Critical Support in the Fight Against Diabetes: 39.3 Billion Lira Financing in 7 Months

Minister of Labor and Social Security Vedat Işıkhan has shared with the public the steps taken to strengthen access to healthcare services for diabetes patients in Turkey. In a statement posted on his social media account, Minister Işıkhan announced that massive financing has been provided under the Social Security Institution (SGK) to facilitate treatment processes and ensure access to medication for citizens battling diabetes. The data covering the January-July period of 2024 highlights the state's determination in combating chronic diseases.

According to the data shared by Minister Işıkhan, a total expenditure of 39.3 billion TL was covered by public resources for the treatment, medication, and medical device needs of diabetes patients in the first seven months of the year. While access to treatment is supported by 248 different diabetes medications currently on the reimbursement list, this strategic move is emphasized as being of critical importance for the management of chronic diseases and the protection of public health.

Background of the Development

Diabetes stands at the center of public health policies in Turkey due to both its high prevalence rates and the long-term health complications it creates. Historically, the SGK has kept the 'Reimbursement List' mechanism constantly updated to alleviate the financial burden on patients in the treatment of chronic diseases. Diabetes, including insulin resistance and type 1/type 2 diabetes, is a process that affects a large segment of society and requires regular monitoring and medication.

Throughout the historical process, the inclusion of medications and medical devices (glucometers, insulin pumps, etc.) used in diabetes treatment into the reimbursement scope has directly improved the quality of life for patients. The Ministry has adopted a holistic health policy by covering not only medication support but also the financing of medical devices that facilitate patient adherence to treatment. This 39.3 billion lira financing is recognized as one of the most concrete reflections of Turkey's social state approach in the field of health.

The fight against diabetes is a multi-layered structure that encompasses not only the provision of medication but also early diagnosis and access to treatment processes. These data from the Ministry prove that Turkey's health system is progressing in line with the goal of minimizing out-of-pocket expenses for citizens while maintaining the financial sustainability of the system.

Expert and Industry Insights

Health economists and endocrinology experts state that this financial support announced by Minister Işıkhan plays a vital role in preventing complications caused by diabetes (such as kidney failure, vision loss, and neuropathy). Experts express that regular medication use reduces hospitalization rates and provides savings in public health expenditures in the long run.

• Facilitating access to medication increases patient adherence, minimizing the risk of complications.
• The diversity of 248 drugs on the reimbursement list supports personalized treatment options.
• Medical device support allows patients to perform their own monitoring at home.
• Financing support contributes to economic productivity by preventing labor loss caused by diabetes.
• Constantly updated reimbursement lists accelerate the delivery of next-generation treatments to citizens.

Industry representatives emphasize that such investments create an environment of trust for the pharmaceutical industry and health technology sector, and that the importance the state places on chronic diseases encourages R&D activities in the sector.

Economic and Social Implications

The economic dimension of diabetes is not limited to medication costs. Untreated diabetes leads to much more costly procedures in later stages, such as dialysis, surgical interventions, and long-term hospitalizations. Therefore, this 39.3 billion lira budget is actually a strategic investment made to prevent larger health expenditures that may arise in the future.

From a social perspective, ensuring access to treatment for diabetes patients makes individuals' participation in social life and the workforce sustainable. Reducing the economic stress experienced by families due to health expenditures reflects positively on the general welfare level of society. This step by the Ministry is evaluated as a social policy tool that strengthens equality of opportunity in accessing health services.

Future Projections and Outlook

Minister Işıkhan's statements signal that support for diabetes patients will continue to increase in the coming period. In future projections, it is expected that innovative steps such as including digital health solutions and remote monitoring systems in the reimbursement scope will be taken.

In coordination with the Ministry of Health and the Ministry of Labor, it is foreseen that educational programs to increase diabetes awareness will be expanded and bureaucratic simplifications will be made to further facilitate patients' access to treatment. In terms of risk management, increasing domestic production capacity to prevent supply chain disruptions in medication access remains a strategic goal on the table.

In conclusion, this massive financing realized in the first seven months of 2024 has once again certified Turkey's determination in the fight against chronic diseases and the strength of its social security system. New steps to facilitate citizens' access to treatment opportunities are expected to maintain their place on the agenda in the coming months.